
A recent study compared various strategies for managing secondary hypogammaglobulinemia in patients with neuroimmunological disorders. The strategies analyzed included reducing anti-CD20 dosage and frequency, IVIG/SCIG treatment, anti-CD20 cessation, and switching disease-modifying therapies (DMTs). Out of 257 patients, 30 received treatment for hypogammaglobulinemia. The results indicated that IVIG/SCIG showed the highest increase in IgG levels per year (674.0 mg/dL) and reduced infection frequency and severity. Stopping anti-CD20 therapy and switching DMTs also increased IgG levels and potentially lowered infection risk.
Like
Save
Share